Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
62K characters. Original on sec.gov ·
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| Operating Segments Trends and Results | |||||
Intel Products
Intel Products consists substantially of the design, development, marketing, sale, support and servicing of CPUs and related semiconductor products for third-party customers. Intel Products is comprised of two operating segments: Client Computing and Physical AI Group, or CCPG, and Data Center and Artificial Intelligence, or DCAI. CCPG (formerly the Client Computing Group, or CCG) delivers platforms and processors that power PCs and edge devices, enabling enhanced performance, connectivity and user experiences for consumer and commercial markets, with capabilities that also support retail, industrial robotics and AI ecosystems at the edge. DCAI delivers workload-optimized solutions based upon our x86 architecture for data centers, including CPUs, AI accelerators, NICs, IPUs and purpose-built silicon, enabling performance and scalability for cloud, enterprise, telecommunication and HPC environments. The manufacturing of our Intel Products offerings is performed by Intel Foundry and, to a lesser extent, by certain third-party manufacturers.
Intel Products Financial Performance1
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||||||||
| Sep 26, 2026 | Sep 26, 2026 | |||||||||||||||||||||||||||||||||||||
| ($ In Millions) | CCPG | DCAI | Total | CCPG | DCAI | Total | ||||||||||||||||||||||||||||||||
| Revenue | $ | 8,097 | $ | 7,318 | $ | 15,415 | $ | 24,701 | $ | 18,632 | $ | 43,333 | ||||||||||||||||||||||||||
| Cost of sales and operating expenses | 5,812 | 4,279 | 10,091 | 17,557 | 11,577 | 29,134 | ||||||||||||||||||||||||||||||||
| Operating income | $ | 2,285 | $ | 3,039 | $ | 5,324 | $ | 7,144 | $ | 7,055 | $ | 14,199 | ||||||||||||||||||||||||||
| Operating margin % | 28% | 42% | 35% | 29% | 38% | 33% | ||||||||||||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||||||||
| Sep 27, 2025 | Sep 27, 2025 | |||||||||||||||||||||||||||||||||||||
| ($ In Millions) | CCPG | DCAI | Total | CCPG | DCAI | Total | ||||||||||||||||||||||||||||||||
| Revenue | $ | 8,535 | $ | 4,117 | $ | 12,652 | $ | 24,035 | $ | 12,182 | $ | 36,217 | ||||||||||||||||||||||||||
| Cost of sales and operating expenses | 5,841 | 3,153 | 8,994 | 16,927 | 10,010 | 26,937 | ||||||||||||||||||||||||||||||||
| Operating income | $ | 2,694 | $ | 964 | $ | 3,658 | $ | 7,108 | $ | 2,172 | $ | 9,280 | ||||||||||||||||||||||||||
| Operating margin % | 32% | 23% | 29% | 30% | 18% | 26% |
1 Operating segment results include intersegment financial activity; refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for a reconciliation between our operating segment and consolidated financial results for the periods presented.
Operating Segment Revenue Summary
Q3 2026 vs. Q3 2025
Total Intel Products revenue was $15.4 billion in Q3 2026, up $2.8 billion from Q3 2025.
▪CCPG revenue decreased $438 million from Q3 2025. Client revenue (collectively notebook and desktop) was $6.9 billion in Q3 2026, down $424 million from Q3 2025, driven by a 14% decrease in volume due to lower demand and a competitive market environment. The decrease in client revenue was partially offset by a 9% increase in ASPs, primarily resulting from pricing actions, in part to offset higher input costs, as well as a higher mix of premium products sold in Q3 2026. Other CCPG revenue was $1.2 billion in Q3 2026, down $14 million from Q3 2025.
▪DCAI revenue increased $3.2 billion from Q3 2025, driven by higher server revenue, which increased $2.5 billion in Q3 2026 due to ASP increases of 54%. The majority of the increase in server ASPs resulted from a higher mix of premium products sold in Q3 2026, with demand-based pricing actions contributing to a lesser extent, in part to offset higher input costs. Server volume increased 10% compared to Q3 2025, driven by higher hyperscaler demand. Industry-wide supply constraints impacted our ability to fully meet demand for certain products in Q3 2026, a trend which we expect will extend into next year. Other DCAI revenue was $1.4 billion in Q3 2026, up $743 million from Q3 2025, driven by higher demand for purpose-built silicon.
![]() | MD&A | 33 |
YTD 2026 vs. YTD 2025
Total Intel Products revenue was $43.3 billion in YTD 2026, up $7.1 billion from YTD 2025.
▪CCPG revenue increased $666 million from YTD 2025. Client revenue (collectively notebook and desktop) was $21.3 billion in YTD 2026, up $763 million from YTD 2025, driven by a 17% increase in ASPs. The majority of the increase in ASPs resulted from a higher mix of premium products sold in YTD 2026, with pricing actions contributing to a lesser extent, in part to offset higher input costs. This increase in client revenue was partially offset by a 12% decrease in volume compared to YTD 2025. Market demand exceeded our available product supply during the first half of 2026 due to industry-wide supply constraints. In comparison, during Q3 2026 demand for client products eased, reducing the impact of these constraints. Other CCPG revenue was $3.4 billion in YTD 2026, down $97 million from YTD 2025.
▪DCAI revenue increased $6.5 billion from YTD 2025, driven by higher server revenue, which increased $5.2 billion in YTD 2026 due to a 44% increase in ASPs. The majority of the increase in server ASPs resulted from a higher mix of premium products sold in YTD 2026, with demand-based pricing actions contributing to a lesser extent, in part to offset higher input costs. Server volume increased 4% compared to YTD 2025, driven by higher hyperscaler demand. Market demand exceeded our available product supply during YTD 2026 due to industry-wide supply constraints, which impacted our ability to fully meet demand. Though we continue to add capacity in our factories to increase supply and mitigate these constraints, we expect industry-wide supply constraints to persist into next year. Other DCAI revenue was $3.3 billion in YTD 2026, up $1.3 billion from YTD 2025, driven by higher demand for purpose-built silicon.
Segment Operating Income Summary
Q3 2026 vs. Q3 2025
Total Intel Products operating income was $5.3 billion in Q3 2026, up $1.7 billion from Q3 2025.
▪CCPG operating income decreased $409 million from Q3 2025, driven by $763 million of higher period charges primarily resulting from higher inventory-related charges recognized in Q3 2026 as we aligned product mix with customer demand. The decrease in operating income was partially offset by $228 million of lower operating expenses primarily resulting from the effects of various cost-reduction measures.
▪DCAI operating income increased $2.1 billion from Q3 2025, driven by $2.2 billion of higher product profit in Q3 2026 resulting from higher server revenue, partially offset by higher server unit costs due to the increased mix of premium products sold in Q3 2026.
YTD 2026 vs. YTD 2025
Total Intel Products operating income was $14.2 billion in YTD 2026, up $4.9 billion from YTD 2025.
▪CCPG operating income increased $36 million from YTD 2025, driven by $800 million of higher product profit in YTD 2026 resulting from higher client revenue, partially offset by higher client unit costs due to the increased mix of premium products sold in YTD 2026. Operating income also benefited from $735 million of lower operating expenses resulting from the effects of various cost-reduction measures. These benefits were partially offset by $1.5 billion of higher period charges, primarily inventory-related charges recognized in YTD 2026 as we aligned product mix with customer demand.
▪DCAI operating income increased $4.9 billion from YTD 2025, driven by $4.5 billion of higher product profit in YTD 2026 resulting from higher server revenue in YTD 2026, partially offset by higher server unit costs due to the increased mix of premium products sold in YTD 2026. Operating income also benefited from $403 million of lower period charges in YTD 2026 primarily resulting from the absence of the Gaudi AI accelerator inventory-related charges incurred in YTD 2025.
Intel Foundry
Intel Foundry, comprised of technology development, manufacturing and foundry services, develops new leading-edge semiconductor process technologies and advanced packaging technologies and provides manufacturing, assembly and test and advanced packaging capacity and design enablement solutions across multiple nodes and platforms. We continue to innovate and advance leading-edge semiconductor process technology and manufacturing in the U.S., where we are the only company conducting both leading-edge logic R&D and high-volume manufacturing. At present, substantially all of our Intel Foundry business supports internal manufacturing for Intel Products; however, we are offering our Intel Foundry services to external customers and aim to develop a more significant external foundry business in the future.
![]() | MD&A | 34 |
Intel Foundry Financial Performance1
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||
| ($ In Millions) | Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | ||||||||||||||||||||||||||||
| Revenue | $ | 6,697 | $ | 4,235 | $ | 17,883 | $ | 13,319 | ||||||||||||||||||||||||
| Cost of sales and operating expenses | 8,550 | 6,556 | 24,262 | 21,128 | ||||||||||||||||||||||||||||
| Operating loss | $ | (1,853) | $ | (2,321) | $ | (6,379) | $ | (7,809) | ||||||||||||||||||||||||
| Operating loss % | (28)% | (55)% | (36)% | (59)% |
1 Operating segment results include intersegment financial activity; refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for a reconciliation between our operating segment and consolidated financial results for the periods presented.
Operating Segment Revenue Summary
Q3 2026 vs. Q3 2025
Revenue was $6.7 billion in Q3 2026, up $2.5 billion from Q3 2025. Intersegment revenue was $6.3 billion in Q3 2026, up $2.1 billion from Q3 2025, driven by higher wafer volumes from Intel 18A, Intel 3 and Intel 4 process nodes, which carry higher ASPs relative to predecessor process nodes and higher intersegment back-end services revenue. External revenue was $411 million in Q3 2026, up $379 million from Q3 2025, primarily due to revenue recognized under a non-recurring foundry contract.
YTD 2026 vs. YTD 2025
Revenue was $17.9 billion in YTD 2026, up $4.6 billion from YTD 2025. Intersegment revenue was $17.0 billion in YTD 2026, up $3.8 billion from YTD 2025, driven by higher wafer volumes from Intel 18A, Intel 3 and Intel 4 process nodes, which carry higher ASPs relative to predecessor process nodes and higher intersegment back-end services revenue. External revenue was $878 million in YTD 2026, up $793 million from YTD 2025, primarily due to Altera's transition to an external customer following our Q3 2025 deconsolidation of the business**.**
Segment Operating Loss Summary
Q3 2026 vs. Q3 2025
Operating loss was $1.9 billion in Q3 2026 compared to an operating loss of $2.3 billion in Q3 2025, driven by $793 million of lower period charges in Q3 2026, including lower costs associated with our Intel 3 and Intel 4 process nodes and the sell-through of inventory with lower of cost or net realizable value intersegment reserves during the early ramp of our Intel 18A process node. These benefits were partially offset by $219 million of higher operating expenses primarily related to investments in our process technology.
YTD 2026 vs. YTD 2025
Operating loss was $6.4 billion in YTD 2026 compared to an operating loss of $7.8 billion in YTD 2025, driven by $2.6 billion of lower period charges primarily resulting from lower costs associated with our Intel 3, Intel 4 and Intel 7 process nodes. The lower period charges also reflect the absence of $797 million of non-cash asset impairment and accelerated depreciation charges we recognized in Q2 2025 related to certain manufacturing assets that were determined at such time to have no remaining operational use, as well as $601 million of lower inventory charges driven by the intersegment sell-through of inventory with lower of cost or net realizable value intersegment reserves during the early ramp of our Intel 18A process node. These benefits were partially offset by $936 million of lower product profit in YTD 2026 primarily resulting from an increased mix of higher-cost wafers manufactured on our Intel 18A process node and by $231 million of higher operating expenses primarily related to investments in our process technology.
![]() | MD&A | 35 |
All Other
Our "All Other" category includes the results of operations from non-reportable segments, including our Mobileye business, our IMS business, start-up businesses that support our initiatives and historical results of operations from divested businesses, including Altera. Mobileye, a publicly traded company, is a global leader in driving assistance and self-driving solutions, with a product portfolio designed to encompass the entire stack required for assisted and autonomous driving, including compute platforms, computer vision and machine learning-based perception, mapping and localization, driving policy and active sensors. IMS specializes in developing and manufacturing multi-beam mask writing tools. Altera, a business offering programmable semiconductors, primarily FPGAs, and related products for a broad range of applications, was previously a wholly owned subsidiary but was deconsolidated from our Consolidated Condensed Financial Statements effective September 12, 2025, following the closing of our sale of 51% of Altera's issued and outstanding common stock. Altera's financial results of operations were included in our "All Other" category through September 11, 2025.
All Other Financial Performance1
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| ($ In Millions) | Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | ||||||||||||||||||||||
| Revenue | $ | 692 | $ | 993 | $ | 2,021 | $ | 2,989 | ||||||||||||||||||
| Cost of sales and operating expenses | 513 | 893 | 1,510 | 2,717 | ||||||||||||||||||||||
| Operating income | $ | 179 | $ | 100 | $ | 511 | $ | 272 | ||||||||||||||||||
| Operating margin % | 26% | 10% | 25% | 9% |
1 Operating segment results include intersegment financial activity; refer to "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements for a reconciliation between our operating segment and consolidated financial results for the periods presented.
Operating Segment Revenue Summary
Q3 2026 vs. Q3 2025
All Other revenue was $692 million, down $301 million from Q3 2025, primarily as a result of the Q3 2025 deconsolidation of Altera. Mobileye revenue was $493 million in Q3 2026, roughly flat with Q3 2025.
YTD 2026 vs. YTD 2025
All Other revenue was $2.0 billion, down $968 million from YTD 2025, primarily as a result of the Q3 2025 deconsolidation of Altera. This decrease was partially offset by higher Mobileye revenue in YTD 2026, which totaled $1.6 billion, up $109 million from YTD 2025, driven by higher demand for Mobileye EyeQ* products.
Segment Operating Income Summary
Q3 2026 vs. Q3 2025 and YTD 2026 vs. YTD 2025
All Other operating income was $179 million in Q3 2026, up $79 million from Q3 2025, and $511 million in YTD 2026, up $239 million from YTD 2025, driven by higher operating income from our other businesses in Q3 2026 and YTD 2026, partially offset by the absence of Altera operating margin in Q3 2026 and YTD 2026.
![]() | MD&A | 36 |
| Consolidated Condensed Results of Operations | |||||
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
| Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||
| (In Millions, Except Per Share Amounts) | Amount | % of Net Revenue****1 | Amount | % of Net Revenue****1 | Amount | % of Net Revenue****1 | Amount | % of Net Revenue****1 | ||||||||||||||||||||||||||||||||||||||||||
| Net revenue | $ | 16,513 | 100.0 | % | $ | 13,653 | 100.0 | % | $ | 46,218 | 100.0 | % | $ | 39,179 | 100.0 | % | ||||||||||||||||||||||||||||||||||
| Cost of sales | 9,417 | 57.0 | % | 8,435 | 61.8 | % | 27,266 | 59.0 | % | 25,747 | 65.7 | % | ||||||||||||||||||||||||||||||||||||||
| Gross profit | 7,096 | 43.0 | % | 5,218 | 38.2 | % | 18,952 | 41.0 | % | 13,432 | 34.3 | % | ||||||||||||||||||||||||||||||||||||||
| Research and development | 3,490 | 21.1 | % | 3,231 | 23.7 | % | 10,233 | 22.1 | % | 10,555 | 26.9 | % | ||||||||||||||||||||||||||||||||||||||
| Marketing, general, and administrative | 1,030 | 6.2 | % | 1,129 | 8.3 | % | 3,243 | 7.0 | % | 3,450 | 8.8 | % | ||||||||||||||||||||||||||||||||||||||
| Restructuring and other charges | 54 | 0.3 | % | 175 | 1.3 | % | 4,294 | 9.3 | % | 2,221 | 5.7 | % | ||||||||||||||||||||||||||||||||||||||
| Operating income (loss) | 2,522 | 15.3 | % | 683 | 5.0 | % | 1,182 | 2.6 | % | (2,794) | (7.1) | % | ||||||||||||||||||||||||||||||||||||||
| Gains (losses) on equity investments, net | 330 | 2.0 | % | 221 | 1.6 | % | 219 | 0.5 | % | 611 | 1.6 | % | ||||||||||||||||||||||||||||||||||||||
| Interest and other, net | 1,130 | 6.8 | % | 3,670 | 26.9 | % | (12,184) | (26.4) | % | 3,402 | 8.7 | % | ||||||||||||||||||||||||||||||||||||||
| Income (loss) before taxes | 3,982 | 24.1 | % | 4,574 | 33.5 | % | (10,783) | (23.3) | % | 1,219 | 3.1 | % | ||||||||||||||||||||||||||||||||||||||
| Provision for (benefit from) taxes | 462 | 2.8 | % | 304 | 2.2 | % | 826 | 1.8 | % | 860 | 2.2 | % | ||||||||||||||||||||||||||||||||||||||
| Net income (loss) | 3,520 | 21.3 | % | 4,270 | 31.3 | % | (11,609) | (25.1) | % | 359 | 0.9 | % | ||||||||||||||||||||||||||||||||||||||
| Less: net income (loss) attributable to non-controlling interests | 200 | 1.2 | % | 207 | 1.5 | % | (168) | (0.4) | % | 35 | 0.1 | % | ||||||||||||||||||||||||||||||||||||||
| Net income (loss) attributable to Intel | $ | 3,320 | 20.1 | % | $ | 4,063 | 29.8 | % | $ | (11,441) | (24.8) | % | $ | 324 | 0.8 | % | ||||||||||||||||||||||||||||||||||
| Earnings (loss) per share attributable to Intel—diluted****2 | $ | 0.60 | $ | 0.90 | $ | (2.22) | $ | 0.07 | ||||||||||||||||||||||||||||||||||||||||||
1 Totals may not sum due to rounding.
2 For the three months ended September 26, 2026 and three and nine months ended September 27, 2025, earnings per share attributable to Intel-diluted has been calculated by adjusting net income attributable to Intel for the gain of $120 million and loss of $2 million, respectively, related to the mark-to-market of that portion of the derivative liability that is attributable to 5 million and 342 thousand, respectively, contingent Escrowed Shares that were included in the weighted average shares of common stock outstanding-diluted during the period.
![]() | MD&A | 37 |
Consolidated Revenue
| Consolidated Revenue Walk $B1 | |||||||||||


1 Excludes intersegment revenue; totals may not sum due to rounding.
Q3 2026 vs. Q3 2025
Our revenue was $16.5 billion in Q3 2026, up $2.9 billion from Q3 2025, driven by higher Intel Products revenue. Intel Products revenue increased 22% from Q3 2025, driven by higher DCAI revenue, partially offset by lower CCPG revenue. DCAI revenue increased 78% from Q3 2025, driven by a higher mix of premium products sold, with demand-based pricing actions contributing to a lesser extent, in part to offset higher input costs. CCPG revenue decreased 5% from Q3 2025 driven by lower client volume due to lower demand and a competitive market environment, partially offset by higher client ASPs. We expect strong demand for our data center products to continue in Q4 2026 and beyond, while trends impacting client demand are expected to worsen in Q4 2026 and persist into 2027. Intel Foundry revenue increased from Q3 2025, primarily due to revenue recognized under a non-recurring foundry contract. All Other revenue decreased from Q3 2025 due to Altera's transition to an external customer following the deconsolidation of Altera in Q3 2025.
In Q3 2026, as in YTD 2026, our revenue was impacted by industry-wide supply constraints with respect to substrates, memory and other critical components. Among other things, these constraints impacted our availability of product to meet demand, particularly for our data center CPUs that rely upon substrates for the advanced packaging utilized in their manufacture. Other parts of the market, especially those that are more price-sensitive such as the client markets, have seen demand impacted adversely by high memory prices as a result of memory supply constraints. During Q3 2026, customer demand for certain client products eased as compared to the first half of the year, while demand for certain data center products continued to exceed available supply. We expect the industry-wide shortages of substrates, memory and other critical components to persist into next year, which may limit our ability to fully meet demand in some areas and adversely impact demand in other areas. We continue to take actions to mitigate these constraints where possible, including adding capacity in our manufacturing facilities and securing supplies through long-term agreements, though our ability to mitigate the impact of some of the constraints, such as those with respect to memory, is very limited.
YTD 2026 vs. YTD 2025
Our revenue was $46.2 billion in YTD 2026, up $7.0 billion from YTD 2025, driven by higher Intel Products revenue. Intel Products revenue increased 20% from YTD 2025, driven by higher DCAI and CCPG revenue. DCAI revenue increased 53% from YTD 2025, and CCPG revenue increased 3% from YTD 2025. These increases were driven by a higher mix of premium products sold, with demand-based pricing actions contributing to a lesser extent, in part to offset higher input costs in YTD 2026. Intel Foundry revenue increased, and All Other revenue decreased, compared to YTD 2025, primarily due to Altera's transition to an external customer following the deconsolidation of Altera in Q3 2025.
In YTD 2026, our revenue was impacted by the industry-wide supply constraints discussed above under "Q3 2026 vs. Q3 2025."
![]() | MD&A | 38 |
Consolidated Gross Profit
We derived a substantial majority of our consolidated gross profit in Q3 2026 and in YTD 2026 from our Intel Products business sales through our CCPG and DCAI operating segments.
| Gross Profit $B1 | |||||
| (Percentages in chart indicate gross profit as a percentage of total revenue) |


1 Amounts presented may not recalculate due to rounding.
Q3 2026 vs. Q3 2025
Our consolidated gross profit in Q3 2026 increased by $1.9 billion, or 36%, compared to Q3 2025, driven by $1.6 billion of higher product profit in Q3 2026, primarily resulting from higher revenue, partially offset by higher unit costs due to an increased mix of premium products sold in Q3 2026. Gross profit also benefited from $328 million of lower period charges as a result of lower costs associated with our Intel 3 and Intel 4 process nodes, partially offset by higher inventory-related charges recognized in Q3 2026 as we aligned client product mix with customer demand.
YTD 2026 vs. YTD 2025
Our consolidated gross profit in YTD 2026 increased by $5.5 billion, or 41%, compared to YTD 2025, driven by $2.9 billion of higher product profit in YTD 2026, primarily resulting from higher revenue, partially offset by higher unit costs due to an increased mix of premium products sold in YTD 2026. Gross profit also benefited from $2.6 billion of lower period charges including lower costs associated with our Intel 3, Intel 4 and Intel 7 process nodes, the absence in YTD 2026 of $797 million of non-cash asset impairment and accelerated depreciation charges we recognized in Q2 2025 related to certain manufacturing assets that were determined at such time to have no remaining operational use, and lower inventory-related charges driven by the sell-through of inventory with lower of cost or net realizable value reserves during the early ramp of our Intel 18A process node.
![]() | MD&A | 39 |
Consolidated R&D and MG&A Expenses
Total R&D and MG&A expenses were $4.5 billion for Q3 2026, up 4% from Q3 2025, and $13.5 billion for YTD 2026, down 4% from YTD 2025. These expenses represent 27.4% and 31.9% of revenue for Q3 2026 and Q3 2025, respectively, and 29.2% and 35.7% of revenue for YTD 2026 and YTD 2025, respectively. In support of our strategy, as described in our 2025 Form 10-K, we continue to make investments to advance our product and process technology roadmaps. As a result of our 2025 and 2024 Restructuring Plans and related cost-reduction measures and the deconsolidation of Altera in Q3 2025, we expect total R&D and MG&A expenses to decrease in 2026 relative to recent historical periods.
| Research and Development $B | Marketing, General, and Administrative $B | ||||||||||
| (Percentages in chart indicate operating expenses as a percentage of total revenue) | |||||||||||


Research and Development
Q3 2026 vs. Q3 2025
R&D expenses were $259 million, or 8%, higher in Q3 2026 as compared to Q3 2025, driven by investments in our process technology and products and higher incentive-based cash compensation in Q3 2026, partially offset by lower expenses in Q3 2026 as a result of the Q3 2025 deconsolidation of Altera.
YTD 2026 vs. YTD 2025
R&D expenses were $322 million, or 3%, lower in YTD 2026 as compared to YTD 2025, driven by the effects of various cost-reduction measures and lower expenses in YTD 2026 as a result of the Q3 2025 deconsolidation of Altera, partially offset by higher incentive-based cash compensation in YTD 2026.
Marketing, General, and Administrative
Q3 2026 vs. Q3 2025
MG&A expenses were $99 million, or 9%, lower in Q3 2026 as compared to Q3 2025, driven by the effects of various cost-reduction measures and lower expenses in Q3 2026 as a result of the Q3 2025 deconsolidation of Altera, partially offset by higher share-based compensation in Q3 2026.
YTD 2026 vs. YTD 2025
MG&A expenses were $207 million, or 6%, lower in YTD 2026 as compared to YTD 2025, driven by the effects of various cost-reduction measures and lower expenses in YTD 2026 as a result of the Q3 2025 deconsolidation of Altera, partially offset by higher share-based compensation in YTD 2026.
![]() | MD&A | 40 |
Restructuring and Other Charges
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | ||||||||||||||||||||||
| Employee severance and benefit arrangements | $ | 55 | $ | 146 | $ | 290 | $ | 1,754 | ||||||||||||||||||
| Litigation charges and other | 22 | 33 | 60 | 52 | ||||||||||||||||||||||
| Asset impairment charges | (23) | (4) | 3,944 | 415 | ||||||||||||||||||||||
| Total restructuring and other charges | $ | 54 | $ | 175 | $ | 4,294 | $ | 2,221 |
In Q2 2025, we announced and commenced the 2025 Restructuring Plan, which was designed to streamline our organizational structure, enable us to focus on our core businesses and lower our overall operating expenses. Refer to "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements for further information. The substantial majority of the actions contemplated by the 2025 Restructuring Plan were completed in 2025, with the remainder expected to be completed by Q4 2026.
The 2024 Restructuring Plan, which we initiated in Q3 2024, was substantially complete by the end of 2025, with the remainder expected to be completed by Q4 2026.
Q3 2026 vs. Q3 2025 and YTD 2026 vs. YTD 2025
Employee severance and benefit arrangements included charges of $55 million in Q3 2026 and $290 million in YTD 2026, primarily relating to the 2025 Restructuring Plan, compared to $146 million in Q3 2025 and $1.8 billion in YTD 2025. Charges in Q3 2025 and YTD 2025 primarily related to the 2025 Restructuring Plan, with the remaining charges relating to the 2024 Restructuring Plan.
Asset impairment charges in YTD 2026 included non-cash goodwill impairment charges of $3.9 billion. Refer to "Note 10: Goodwill" within Notes to Consolidated Condensed Financial Statements. In YTD 2025, asset impairment charges included non-cash charges associated with the 2025 Restructuring Plan resulting from the exit of certain non-core lines of business and the consolidation and exit of certain real estate properties.
Gains (Losses) on Equity Investments, Net and Interest and Other, Net
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||
| (In Millions) | Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | |||||||||||||||||||||||||||||||||||||
| Unrealized gains (losses) on marketable equity investments, net | $ | 12 | $ | 116 | $ | (204) | $ | (234) | |||||||||||||||||||||||||||||||||
| Unrealized gains (losses) on non-marketable equity investments, net1 | 247 | 17 | 359 | 490 | |||||||||||||||||||||||||||||||||||||
| Impairment charges on non-marketable equity investments | (55) | (76) | (209) | (232) | |||||||||||||||||||||||||||||||||||||
| Unrealized gains (losses) on equity investments, net | 204 | 57 | (54) | 24 | |||||||||||||||||||||||||||||||||||||
| Realized gains (losses) on sales of equity investments, net | 126 | 164 | 273 | 587 | |||||||||||||||||||||||||||||||||||||
| Gains (losses) on equity investments, net | $ | 330 | $ | 221 | $ | 219 | $ | 611 | |||||||||||||||||||||||||||||||||
| Interest and other, net | $ | 1,130 | $ | 3,670 | $ | (12,184) | $ | 3,402 |
1 Unrealized gains (losses) on non-marketable investments include observable price adjustments and our share of equity method investee gains (losses) and certain distributions.
Q3 2026 vs. Q3 2025
In Q3 2026, gains (losses) on equity investments, net were driven by unrealized gains on non-marketable equity investments, which included $351 million of upward observable price adjustments related to two investments, partially offset by equity method investment losses.
In Q3 2025, gains (losses) on equity investments, net were driven by realized gains on opportunistic sales of marketable equity securities that had appreciated in value, along with unrealized gains on marketable equity securities, reflecting favorable market conditions and portfolio performance during the quarter.
In Q3 2026 and Q3 2025, interest and other, net included a $1.0 billion net gain and a $1.7 billion net loss, respectively, from the change in fair value of the derivative liability for the Escrowed Shares. Refer to "Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within Notes to Consolidated Condensed Financial Statements. In Q3 2025, we recognized a $5.5 billion pre-tax gain in interest and other, net related to the sale of 51% of Altera. Refer to "Note 9: Acquisitions and Divestitures" within Notes to Consolidated Condensed Financial Statements.
![]() | MD&A | 41 |
YTD 2026 vs. YTD 2025
In YTD 2026, gains (losses) on equity investments, net were driven by $531 million in upward observable price adjustments, the majority of which related to two investments, and realized gains on sales of equity investments, partially offset by impairment charges on non-marketable equity investments, mark-to-market losses on marketable equity investments and equity method investee losses.
In YTD 2025, gains (losses) on equity investments, net were driven by $486 million in upward observable price adjustments, of which $396 million related to a single investment, and realized gains on sales of equity investments, partially offset by unrealized gains (losses) on marketable equity investments and impairment charges on non-marketable equity investments.
In YTD 2026 and YTD 2025, interest and other, net included a $12.6 billion net loss and a $1.7 billion net loss, respectively, from the change in fair value of the derivative liability for the Escrowed Shares. In addition, interest and other, net in YTD 2026 included a benefit of $223 million resulting from the change in fair value of liquidated damages provisions related to our Ireland SCIP arrangement. Refer to "Note 3: Non-Controlling Interests" within Notes to Consolidated Condensed Financial Statements. In addition to the $5.5 billion pre-tax gain from the sale of 51% of Altera, interest and other, net in YTD 2025 included $191 million in charges related to the sale of our NAND memory business. Refer to "Note 9: Acquisitions and Divestitures" within Notes to Consolidated Condensed Financial Statements.
Provision for (Benefit from) Taxes
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| ($ In Millions) | Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | ||||||||||||||||||||||
| Income (loss) before taxes | $ | 3,982 | $ | 4,574 | $ | (10,783) | $ | 1,219 | ||||||||||||||||||
| Provision for (benefit from) taxes | $ | 462 | $ | 304 | $ | 826 | $ | 860 | ||||||||||||||||||
| Effective tax rate | 11.6 | % | 6.6 | % | (7.7) | % | 70.5 | % |
Q3 2026 vs. Q3 2025 and YTD 2026 vs. YTD 2025
In all periods presented, our provision for income taxes was determined using our estimated annual effective tax rate applied to our year-to-date ordinary income (loss) before taxes, adjusted for discrete items, and we were not able to benefit from our current year domestic loss before taxes due to the domestic valuation allowance. Our provision for taxes increased in Q3 2026, compared to Q3 2025, primarily due to increased profitability in the U.S. Our provision for taxes decreased in YTD 2026, compared to YTD 2025, primarily due to increased share-based compensation deductions.
Net Income (Loss) Attributable to Non-Controlling Interests
Net income (loss) attributable to non-controlling interests is impacted by the minority-owned portion of our consolidated, majority-owned subsidiaries.
| Three Months Ended | Nine Months Ended | |||||||||||||||||||||||||
| (In Millions) | Sep 26, 2026 | Sep 27, 2025 | Sep 26, 2026 | Sep 27, 2025 | ||||||||||||||||||||||
| Ireland SCIP | $ | — | $ | 69 | $ | 135 | $ | 167 | ||||||||||||||||||
| Arizona SCIP | 197 | 158 | 556 | (74) | ||||||||||||||||||||||
| Mobileye | (15) | (14) | (887) | (33) | ||||||||||||||||||||||
| IMS | 18 | (6) | 28 | (25) | ||||||||||||||||||||||
| Total net income (loss) attributable to non-controlling interests | $ | 200 | $ | 207 | $ | (168) | $ | 35 |
Q3 2026 vs. Q3 2025
In Q3 2026 and Q3 2025, net income attributable to non-controlling interests was driven by income earned by Arizona SCIP based on the placement of their manufacturing assets into service.
YTD 2026 vs. YTD 2025
In YTD 2026, net loss attributable to non-controlling interests was driven by a non-cash goodwill impairment charge related to our Mobileye reporting unit in Q1 2026, partially offset by income earned by Arizona SCIP based on the ongoing placement of their manufacturing assets into service. In YTD 2025, net income attributable to non-controlling interests was driven by income earned by Ireland SCIP and income earned by Arizona SCIP in Q3 2025, partially offset by start-up construction expenses incurred by Arizona SCIP during the first half of the year.
In Q2 2026, we acquired all of the outstanding minority holder ownership interests in Ireland SCIP, which was previously one of our majority-owned, consolidated subsidiaries, after which net income attributable to non-controlling interests in Ireland SCIP ceased. See "Note 3: Non-Controlling Interests" within Notes to Consolidated Condensed Financial Statements.
![]() | MD&A | 42 |
Liquidity and Capital Resources
We believe we have sufficient sources of funding to meet our business requirements for the next 12 months and in the longer term. Our primary sources of liquidity are cash generated by operations and our total cash and short-term investments, as shown in the following table. These sources may be further supplemented by our drawn and undrawn committed credit facilities and other borrowing capacity, recent equity securities agreements and issuances, possible future debt and equity issuances pursuant to our shelf registration statement and monetization of non-core assets.
Short-Term Investing and Borrowing
When assessing our current sources of liquidity, we consider our total cash and short-term investments balances as follows:
| (In Millions) | Sep 26, 2026 | Dec 27, 2025 | ||||||||||||
| Cash and cash equivalents | $ | 21,846 | $ | 14,265 | ||||||||||
| Short-term investments | 32,159 | 23,151 | ||||||||||||
| Total cash and short-term investments | $ | 54,005 | $ | 37,416 | ||||||||||
| Total debt | $ | 50,134 | $ | 46,585 |
As described in "Common Stock Issuance" at the beginning of this MD&A, in Q3 2026 we received net proceeds of $22.6 billion from a public offering of our common stock. We intend to use the net proceeds for general corporate purposes, including capital expenditures and working capital. Refer to "Note 4: Earnings (Loss) Per Share and Stockholders' Equity" within the Notes to Consolidated Condensed Financial Statements for additional information.
In Q3 2026, we amended our three-year $3.0 billion credit facility maturing January 2029 to a $4.8 billion facility maturing August 2029. We also amended our five-year $7.0 billion credit facility maturing February 2029 to a $9.7 billion facility maturing August 2031. On October 1, 2026, total borrowing capacity under the amended credit facilities increased by $500 million, bringing the total to $15.0 billion, consisting of a $5.0 billion three-year credit facility and a $10.0 billion five-year credit facility.
In Q2 2026, we settled $1.0 billion of our senior notes due May 2026, and we issued a total of $6.5 billion aggregate principal amount of senior notes comprised of $1.0 billion in 4.65% senior notes due 2031, $1.0 billion in 5.00% senior notes due 2033, $2.2 billion in 5.30% senior notes due 2036, $1.8 billion in 6.13% senior notes due 2056, and $500 million in 6.20% senior notes due 2066. We have other potential sources of liquidity including our commercial paper program and our automatic shelf registration statement on file with the SEC, pursuant to which we may offer an unspecified amount of debt, equity and other securities. Under our commercial paper program, we have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion. As of September 26, 2026, we had no commercial paper obligations outstanding and no outstanding borrowings on the revolving credit facilities. As part of our ongoing capital management strategy to optimize our debt portfolio, we may utilize make-whole provisions, tender offers, or open market repurchases of our debt prior to maturity. In Q3 2026, we did not extinguish any debt prior to maturity.
In Q2 2026, we acquired the minority ownership interest in our previously majority-owned and consolidated Ireland SCIP VIE for aggregate cash consideration of $14.2 billion, inclusive of transaction costs. We funded the repurchase of Apollo's non-controlling equity interest through a combination of our existing cash and cash equivalents, short-term investments and a $6.5 billion term loan. The term loan facility was repaid in Q2 2026 using proceeds from the issuance of $6.5 billion aggregate principal amount of senior fixed-rate notes described above. Refer to "Note 11: Borrowings" within Notes to Consolidated Condensed Financial Statements.
In Q1 2026, we settled $1.5 billion of our senior notes due February 2026 and amended our 364-day $5.0 billion credit facility agreement to a three-year $3.0 billion credit facility maturing January 2029 (which facility was further amended in Q3 2026, as described above).
Our total cash and short-term investments and related cash flows may be affected by certain discretionary actions we may take with customers and suppliers to accelerate or delay certain cash receipts or payments to manage liquidity, among other factors, for our strategic business requirements. These actions can include, among others, negotiating with suppliers to optimize our payment terms and conditions, adjusting the amounts and timing of cash flows associated with customer sales programs and collections, managing inventory levels and purchasing practices and selling certain of our accounts receivable on a non-recourse basis to third-party financial institutions. Such actions may result in a benefit or detriment to cash flows in future periods.
We maintain a diverse investment portfolio that we continually analyze based on issuer, industry and country. Substantially all of our investments in debt instruments were in investment-grade securities.
![]() | MD&A | 43 |
Funding Requirements
Our short-term funding requirements include capital expenditures for worldwide manufacturing and assembly and test operations, including investments in our process technology roadmap, investments in our product roadmap, working capital requirements (including commitments and prepayments made to secure supply capacity), partner distributions to our non-controlling interest holder related to Arizona SCIP, reducing outstanding indebtedness, potential acquisitions and strategic investments. Our long-term funding requirements incrementally contemplate investments in significant manufacturing expansion plans and investments to accelerate our process technology development. These plans include expanding existing operations in Arizona, New Mexico and Oregon and a new leading-edge manufacturing facility in Ohio.
In Q1 2026, we entered into long-term arrangements with customers that included deposits totaling $1.7 billion, which were reflected within other accrued liabilities and other long-term liabilities, and for which the related cash was received in Q2 2026. In response to industry shortages of substrates and other components and to support long-term customer arrangements, we continue to enter into long-term agreements with suppliers to secure component supply. Some of these supply arrangements involve prepayments, of which $1.2 billion were made in YTD 2026. Subsequent to Q3 2026, we entered into two agreements to secure future substrate supply. These agreements are expected to accelerate cash outflows in the near term, and we estimate that approximately $3.3 billion of the associated commitments will be paid by the end of 2027. Refer to "Note 14: Commitments and Contingencies" within Notes to Consolidated Condensed Financial Statements for further information.
Subsequent to Q3 2026, we entered into a definitive agreement to acquire 100% of Classiq Technologies Ltd. for approximately $1.9 billion, subject to customary purchase price adjustments. The agreement also provides for up to $350 million of contingent consideration based on the achievement of specified performance milestones. The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other customary closing conditions. We may elect to settle the purchase price in cash or shares of our common stock.
Cash flows from operating, investing, and financing activities were as follows:
| Nine Months Ended | ||||||||||||||
| (In Millions) | Sep 26, 2026 | Sep 27, 2025 | ||||||||||||
| Net cash provided by (used for) operating activities | $ | 13,184 | $ | 5,409 | ||||||||||
| Net cash provided by (used for) investing activities | (20,259) | (8,255) | ||||||||||||
| Net cash provided by (used for) financing activities | 14,761 | 5,738 | ||||||||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $ | 7,686 | $ | 2,892 |
Operating Activities
Operating cash flows consist of net income (loss) adjusted for certain non-cash items and changes in certain assets and liabilities.
Cash provided by operations in the first nine months of 2026 was higher compared to the first nine months of 2025, primarily due to higher revenues and lower operating expenses after adjusting for non-cash items in the first nine months of 2026 compared to the first nine months of 2025. These cash favorable movements were partially offset by higher unfavorable changes in working capital adjustments in the first nine months of 2026 compared to the first nine months of 2025.
Investing Activities
Investing cash flows consist primarily of purchases, sales and maturities of short-term investments, capital expenditures and proceeds from divestitures.
Cash used for investing activities in the first nine months of 2026 was higher compared to the first nine months of 2025, primarily due to higher purchases of short-term investments, net of sales and maturities, lower proceeds from capital-related government incentives, cash used for the acquisition of Mentee Robotics and lower inflows from other investing, as well as the absence of proceeds from the divestiture of our Altera and NAND memory businesses received in the first nine months of 2025. These unfavorable cash movements were partially offset by lower capital expenditures during the first nine months of 2026 compared to the first nine months of 2025.
Financing Activities
Financing cash flows consist primarily of borrowings and repayments of term debt and commercial paper, financing payments for capital expenditures with extended payment terms, proceeds related to strategic initiatives including SCIP partner contributions and equity-related issuances as well as payments related to SCIP partner distributions.
Cash provided by financing activities in the first nine months of 2026 was higher compared to the first nine months of 2025, driven by net proceeds from our public offering of common stock, our issuance of term debt, higher partner contributions and lower financing payments for capital expenditures with extended payment terms in the first nine months of 2026 compared to the first nine months of 2025. These cash favorable movements were partially offset by partner distributions made to Apollo in connection with our repurchase of the 49% minority ownership interest in Ireland SCIP, repayments of term debt, lower net proceeds from common stock and warrant issuances, lower proceeds from Escrowed Shares, higher payments on finance leases, higher restricted stock unit withholdings and the absence of proceeds from sales of subsidiary shares received in the first nine months of 2025.
![]() | MD&A | 44 |
| Risk Factors and Other Key Information | |||||
Previous: Item 1. Financial Statements · Next: Item 1A. Risk Factors
